FDA Says Bladder Drug
Needs Child Warnings

By

Jennifer Corbett Dooren

Updated April 10, 2007 12:01 a.m. ET

WASHINGTON -- The Food and Drug Administration said a drug used to treat overactive-bladder conditions needs more-specific warnings about the potential to cause hallucinations and agitation in children.

The agency said it was proposing to update the precautions section of the drug's label to note that reports of hallucinations and agitation were "prominent among pediatric cases." The drug is sold generically as oxybutynin...